T1	p 51 153	of previously untreated advanced breast cancer -- a cancer and leukemia group B study ( CALGB 8642 ) .
T2	p 536 714	the Cancer and Leukemia Group B ( CALGB ) master metastatic breast cancer protocol . CALGB 8642 randomizes previously untreated metastatic breast cancer patients either to one of
T3	p 723 731	Phase II
T4	p 1258 1266	Patients
T5	p 1279 1293	histologically
T6	p 1305 1329	measurable breast cancer
T7	p 1358 1382	0-1 . Patients could not
T8	p 1388 1435	had prior chemotherapy for metastatic disease .
T9	p 2295 2329	untreated breast cancer patients .
T10	p 2472 2491	patients adequately
T11	p 2524 2555	hematotoxicity ) with amonafide
T12	i 6 17	Amonafide :
T13	i 21 27	active
T14	i 154 163	Amonafide
T15	i 193 210	naphthalic acid .
T16	i 874 882	standard
T17	i 1072 1102	precedes standard chemotherapy
T18	i 1451 1463	chemotherapy
T19	i 2252 2261	amonafide
T20	i 2658 2680	acetylator phenotyping
T21	o 988 1030	survival , toxicity , and overall response
T22	o 1504 1521	visceral crisis .
T23	o 1657 1666	reduction
T24	o 1701 1742	hematotoxicity or lack thereof . Toxicity
T25	o 1757 1770	hematological
T26	o 1800 1817	3 or 4 leukopenia
T27	o 1839 1860	or 4 thrombocytopenia
T28	o 1875 1885	leukopenia
T29	o 1902 1938	thrombocytopenia . The response rate
T30	o 1964 1983	complete response .
T31	o 1989 1997	response
T32	o 2014 2036	hematological toxicity
T33	o 2083 2105	leukopenia grade 3/4 (
T34	o 2176 2204	thrombocytopenia grade 3/4 (
T35	o 2345 2370	steep dose-response curve
T36	o 2418 2468	myelosuppression and response . Rates of responses